Vitamin C Linked to Reduced Mortality in Blood Disorder Patients

A new clinical trial has made a significant connection between vitamin C and reduced mortality rates in individuals at risk of developing blood disorders. The study's findings suggest that vitamin C can enhance the activity of TET enzymes, which regulate gene expression.

Researchers investigated whether supplementing with vitamin C could benefit people at risk of blood cancers by increasing TET enzyme activity. This theory was based on observations that reduced TET enzyme activity is a common feature in some blood cancers.

The EVITA trial involved 109 participants from Denmark and the US who had either a blood disorder with cancerous potential or low-risk blood cancer. Participants were randomly assigned to receive either oral vitamin C supplements (1,000 mg/day) or a placebo for 12 months.

In the initial assessment of the study's main outcome, researchers found that both groups showed similar growth rates of precancerous or cancerous cells.

Researchers conducting the EVITA trial observed notable differences between participants taking vitamin C and those receiving a placebo. Notably, individuals on vitamin C showed altered inflammatory signaling pathways that suggested improved outcomes. Additionally, they experienced fewer instances of anemia, pneumonia, acute aseptic arthritis, and internal bleeding compared to the control group.

Despite these benefits, the vitamin C group reported more gastrointestinal problems than their counterparts who received no treatment. These findings highlight the complex interplay between vitamin C supplementation and its effects on patients with pre-cancerous or early-stage blood cancers.

Over a median follow-up period of 33.6 months, researchers recorded 35 deaths within the intention-to-treat population. A closer examination revealed that 24 of these fatalities occurred in participants who received the placebo, while 11 were from those taking vitamin C.

An exploratory analysis suggested that patients assigned to the vitamin C group had a higher likelihood of survival during follow-up compared to those receiving the placebo. However, due to the preliminary nature of this finding, researchers emphasize that it requires further validation through larger-scale clinical trials before any definitive conclusions can be drawn.

Co-senior author Peter A. Jones expressed cautious optimism regarding the trial's findings, stating that they provide a strong rationale for continued exploration into vitamin C's potential benefits in pre-cancerous or early-stage blood cancers.

The trial's findings have sparked hope that vitamin C could play a role in reducing mortality rates among individuals with pre-cancerous or early-stage blood disorders.

Researchers are being cautious in their interpretation of the results, emphasizing that they do not yet provide sufficient evidence to support new treatment recommendations.

A larger study is needed to confirm the potential benefits of vitamin C in this context, but the preliminary findings have generated enthusiasm for further exploration of its therapeutic possibilities.